Long-Term predictive value of cyclosporine microemulsion C2 level for chronic renal allograft dysfunction

Transplantation Proceedings

Volumn 35, Issue 8, 2003, Pages 2894-2898

  Citterio, F ^a   Scata M C ^a   Pozzetto, U ^a   Nanni, G ^a   Castagneto, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; STEROID THERAPY;

EID: 0347761643     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.10.012     Document Type: Article

References (15)

1. Hariharan S., Johnson C.P., Breshnahan B.A., et al. Improved graft survival after renal transplantation in the United States, 1988-1996. N Engl J Med. 342:2000;605.
2. OPTN/SRTR Annual Report. www.UNOS.org. Accessed December 2002.
3. Cyclosporine microemulsion (Neoral®) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant. 2:2002;148.
4. Cantarovich M., Barkun J.S., Tchervenkov J.I., et al. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hour post-dose levels in stable liver transplant patients. Transplantation. 66:1998;1621.
5. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243.
6. 2 levels is predictive for AUC in lung transplant recipients. J Heart Lung Transplant 21:87, 2002.
7. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation. 72:2001;1024.
8. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation . Transplantation. 68:1999;55.
9. Levy G.A., Thervet E., Lake J., et al. Transplantation. 73:(Suppl 1):2002;S12.
10. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55:1999;713.
11. Barama A., Perner F., Beauregard-Zollinger L., et al. Absorption profiling of cyclosporine therapy for de novo kidney transplantation a prospective randomized study comparing sparse sampling to trough monitoring . Transplantation. 69:2000;S162.
12. Citterio F., Torricelli P., Serino F., et al. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Transplant Proc. 30:1998;1688.
13. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205.
14. Cole E, Maham N, O'Grady C, et al: C-2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. XIX International Congress of the Transplantation Society, 25-30 August 2002, Miami. Abstract 2086.
15. 0. XIX International Congress of the Transplantation Society, 25-30 August 2002, Miami. Abstract 134.